SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (591)10/2/2000 8:12:44 PM
From: tommysdad  Respond to of 3044
 
Um, wow. <eom>



To: scaram(o)uche who wrote (591)10/2/2000 8:20:43 PM
From: keokalani'nui  Respond to of 3044
 
MLNM previously said its CCR2 Mab antagonist is being investigated for restenosis. Much prefer MS. Thank you for the post.

--Wilder



To: scaram(o)uche who wrote (591)10/18/2000 8:01:25 PM
From: scaram(o)uche  Respond to of 3044
 
this will be an interesting one to read......

Requirement of the chemokine receptor CXCR3 for acute allograft rejection

W.H. Hancock, B. Lu, W. Gao, V. Csizmadia, K. Faia, J.A. King, S.T. Smiley, M. Ling, N.P. Gerard, and C.G. Gerard

J. Exp. Med. 2000 192 (10)

p.s. Thanks, Salesperson!!